Indication
Duvyzat is indicated for the treatment of Duchenne muscular dystrophy (DMD) in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment.
Loading your page…
Loading your page…
Muscular Dystrophy, Duchenne
Marketing Authorisation Holder: Italfarmaco S.p.A.
EMA Authorisation: 06/06/2025
INN: givinostat
AI Drug & Interaction Analysis
Free account required
Ask Osler about Duvyzat: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.